Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Safety of sotorasib and panitumumab in advanced KRAS p.G12C-mutated colorectal cancer

ESMO 2021

17 - 21 Sep 2021

Published: 23 Sep 2021

Views: 1233

Rating:

Save

Dr Marwan Fakih - City of Hope Comprehensive Cancer Center, Duarte, USA

Dr Marwan Fakih speaks to ecancer in an online interview for the ESMO 2021 meeting about the CodeBreak 101 study.

He gives the background of the phase Ib study and explains that it aims to evaluate the combination of sotorasib, a KRASG12C inhibitor, and panitumumab, an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer.

Dr Fakih reports that results suggest that this combination was safe and tolerable, with adverse events consistent with what they expected. He concludes by discussing what they hope to discover when the data matures.

Related Videos

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...

Dr Thierry André - Sorbonne Université, Paris, France

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC ( Dr Thierry André - Sorbonne Université, Paris, France )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Potential benefit to response rates from trastuzumab added to perioperative...

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of...

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )

The parotid gland; an unusual site of colorectal cancer metastasis

Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines

The parotid gland; an unusual site of colorectal cancer metastasis ( Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines )

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?

Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru

Targeting BRAF V600E in metastatic colorectal cancer: where are we today? ( Dr Rodrigo Motta Guerrero - ALIADA Contra el Cáncer, San Isidro, Peru )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

More from ecancer